5334-30-5

Basic information

• Product Name: PP3
• Synonyms: 4-AMINO-7-PHENYLPYRAZOL[3,4-D]PYRIMIDINE;4-AMINO-1-PHENYLPYRAZOLE[3,4-D]PYRIMIDINE;4-AMINO-1-PHENYLPYRAZOLO[3,4-D]PYRIMIDINE;1-PHENYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE;PP3;1-Phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ylamine;4-AMINO-1-PHENYLPYRAZOLO[3,4-D]PYRIMIDINE: TECH., 85%;4-Amino-1-phenylpyrazolo3,4-düpyrimidine, tech. 85%
• CAS NO: 5334-30-5
• Molecular Formula: C₁₁H₉N₅
• Molecular Weight: 211.22
• Product Categories: Nucleotides and Nucleosides;Bases & Related Reagents;Nucleotides;Intracellular Signaling;Amines;Aromatics;Heterocycles;Intermediates
• Mol File: 5334-30-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 214-217 °C
• Boiling Point: 364 °C at 760 mmHg
• Flash Point: 173.9 °C
• Appearance: /
• Density: 1.44 g/cm³
• Vapor Pressure: 1.74E-05mmHg at 25°C
• Refractive Index: 1.77
• Storage Temp.: -20°C
• Solubility: DMF, DMSO, Hot methanol
• BRN: 198460
• CAS DataBase Reference: PP3(CAS DataBase Reference)
• NIST Chemistry Reference: PP3(5334-30-5)
• EPA Substance Registry System: PP3(5334-30-5)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-22
• Safety Statements: 36/37/39-26
• Hazardous Substances Data: 5334-30-5(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 5334-30-5 differently. You can refer to the following data:
1. Intermediate in the preparation of various enzymatic inhibitors
2. The Src family of non-receptor tyrosine kinases regulate cell adhesion, growth, and differentiation through activation of multiple intracellular signaling pathways. Normally inactive, Src kinases are transiently activated during mitosis and constitutively activated by abnormal mutations. Several small molecule inhibitors of this signaling pathway have been developed as a therapeuptic strategy to abate abnormal Src kinase activity. PP3 is an inactive analog of the Src tyrosine kinase inhibitors PP1 and PP2 . At concentrations as high as 10 μM, it does not prevent proliferation mediated by a stem cell factor/mast cell growth factor in hematopoietic and cancer cell lines.[Cayman Chemical]

Biological Activity

Negative control for the src kinase inhibitor PP 2 (3-(4-chlorophenyl)1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine ). Inhibits EGFR kinase (IC 50 = 2.7 μ M).

InChI:InChI=1/C11H9N5/c12-10-9-6-15-16(11(9)14-7-13-10)8-4-2-1-3-5-8/h1-7H,(H2,12,13,14)

Upstream product

• 5334-43-0 5-Amino-4-cyano-1-phenylpyrazole 
• 77287-34-4 formamide 
• 108-86-1 bromobenzene 
• 2380-63-4 4-Aminopyrazolo<3,4-d>pyrimidin 
• 591-50-4 iodobenzene 
• 62564-59-4 ethyl N-(4-cyano-1-phenyl-1H-pyrazol-5-yl)formimidate 
• 100-63-0 phenylhydrazine 
• 5334-48-5 4-chloro-1-(phenyl)-1H-pyrazolo[3,4-d]pyrimidine 

Downstream Products

• 21314-17-0 1-phenyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one 
• 87412-76-8 1-phenyl-4-(p-anisyl)pyrazolo<3,4-d>pyrimidine 
• 87412-74-6 1-phenyl-4-(m-anisyl)pyrazolo<3,4-d>pyrimidine 
• 87412-75-7 1-phenyl-4-(o-anisyl)pyrazolo<3,4-d>pyrimidine 
• 87412-79-1 1-phenyl-4-(p-chlorophenyl)pyrazolo<3,4-d>pyrimidine 
• 87412-78-0 1-phenyl-4-(o-chlorophenyl)pyrazolo<3,4-d>pyrimidine 
• 87412-77-9 1-phenyl-4-(m-chlorophenyl)pyrazolo<3,4-d>pyrimidine 
• 87412-72-4 1-phenyl-4-(m-tolyl)pyrazolo<3,4-d>pyrimidine 
• 87412-73-5 1-phenyl-4-(o-tolyl)pyrazolo<3,4-d>pyrimidine 
• 87432-51-7 1-phenyl-4-(pentyloxy)-1H-pyrazolo<3,4-d>pyrimidine 
• 53645-78-6 1-phenyl-4-phenylpyrazolo<3,4-d>pyrimidine 
• 1454789-02-6 6-cyano-7-imino-5-ethyl-N¹-phenyl-1, 7-dihydropyrazolo[3', 4':4, 5]pyrimido[1, 6-a]pyrimidine 
• 1454789-01-5 6-cyano-7-imino-N¹-phenyl-1,7-dihydropyrazolo[3',4':4,5]pyrimido[1,6-a]pyrimidine 
• 1448550-36-4 C₂₅H₂₃N₇O₂ 

Relevant articles and documents

Synthesis and characterization of two novel organic-inorganic compounds based on tetrahexyl and Tetraheptyl ammonium ions and the preyssler anion and their catalytic activities in the synthesis of 4-aminopyrazolo[3,4-d]- pyrimidines

Two novel organic-inorganic compounds based on tetrahexylammonium (THA) and tetraheptylammonium (THPA) ions and the Preyssler anion, [NaP5W30O110]14-, were synthesized and formulated as (THA)7.7H6.3 [NaP5W30O110] (A) and (THPA)7.5 H6.5[N aP5W30O110] (B).

Pyrimidine compound with pyrazolo [3, 4-d] as parent nucleus and preparation method thereof

The invention discloses a pyrimidine compound with pyrazolo [3, 4-d] as a parent nucleus and a preparation method thereof. The invention relates to pyrazolo [3, 4-d] pyrimidine derivatives shown in ageneral formula (I), a preparation method of the pyrazol

Novel pyrazolopyrimidine derivatives targeting COXs and iNOS enzymes; Design, synthesis and biological evaluation as potential anti-inflammatory agents

A novel set of 4-substituted-1-phenyl-pyrazolo[3,4-d]pyrimidine and 5-substituted-1-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives were synthesized and evaluated as potential anti-inflammatory agents. The newly prepared compounds were assessed through the examination of their in vitro inhibition of four targets; cyclooxygenases subtypes (COX-1 and COX-2), inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-κB). Compounds 8a, 10c and 13c were the most potent and selective ligands against COX-2 with inhibition percentages of 79.6%, 78.7% and 78.9% at a concentration of 2 μM respectively, while compound 13c significantly inhibited both COX subtypes. On the other hand, fourteen compounds showed high iNOS inhibitory activities with IC50 values in the range of 0.22-8.5 μM where the urea derivative 11 was the most active compound with IC50 value of 0.22 μM. Most of the tested compounds were found to be devoid of inhibitory activity against NF-kB. Moreover, almost all compounds were not cytotoxic, (up to 25 μg/ml), against a panel of normal and cancer cell lines. The in silico docking results were in agreement with the in vitro inhibitory activities against COXs and iNOS enzymes. The results of in vivo anti-inflammatory and antinociceptive studies were consistent with that of in vitro studies which confirmed that compounds 8a, 10c and 13c have significant anti-inflammatory and analgesic activities comparable to that of the control, ketorolac. Taken together, dual inhibition of COXs and iNOS with novel pyrazolopyrimidine derivatives is a valid strategy for the development of anti-inflammatory/ analgesic agents with the probability of fewer side effects.